Applications

1445 – PD-L1 testing for access to pembrolizumab in patients with recurrent or progressive metastatic bladder cancer that has recurred or progressed following platinum-based chemotherapy

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Pre-assessment
  • Type -
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome -

Application details

Reason for application

New MBS item.

Service or technology in this application

ImmunoHistoChemistry test for evaluation of Programmed Cell Death-Ligand 1 (PD-L1) expression to determine eligibility for treatment with pembrolizumab.

Type: Investigative

Medical condition this application addresses

Locally advanced/unresectable or metastatic urinary bladder cancer.

Application documents

PICO confirmation

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: 11 - 12 August 2016
  • ESC meeting: -
  • MSAC meeting: -